Tagged with medicine

Global The CGT field is undergoing a critical transformation from boom to thoughtful reset. While early enthusiasm brought a rush of investment and regulatory attention, the sector is now refining its ambitions, weeding out unviable approaches, and laying the foundations for long-term impact. Companies, regulators, and healthcare systems are rethinking what…

USA John Murphy, President and CEO of the Association for Accessible Medicines (AAM), outlines a compelling vision for improving access to high-quality, affordable medicines in the US. He stresses that by directing greater focus to the generic and biosimilar market, tackling structural challenges, safeguarding supply chains, and enabling strategic domestic investment,…

Denmark Morten Graugaard, former partner at Novo Holdings A/S, a global life science investment fund, became CEO of Orbis Medicine in February 2025. Drawing on his deep experience in life sciences and venture capital, he has led the company to raise EUR 116 million in funding, positioning Orbis as a pioneer…

Africa Writing in the July 2025 edition of DIA’s Global Forum magazine, Alex Juma Ismail of the African Union Development Agency – New Partnership for Africa’s Development (AUDA-NEPAD) and Vicki Gold, a consultant to the Gates Foundation, unveil the “Continental List of Human Medicinal Products” pilot—a first-of-its-kind initiative led by the…

France Professor Bana Jabri, Director of the Institut Imagine, brings a transatlantic perspective to advancing genetic medicine. After 25 years in the US, she now leads efforts in France to harness genomic technologies, foster interdisciplinary collaboration, and modernise academic–industry partnerships. Her vision calls for strategic investment, institutional autonomy, and greater risk…

Denmark Since stepping into the role of Chair of the Danish Medicines Council in early 2025, Birgitte Klindt Poulsen has been navigating the delicate balance between accelerating patient access to innovation and maintaining the rigour of independent, evidence-based evaluation. In this interview, she shares how the Council is adapting to a…

Denmark As Denmark launches its ambitious Life Science Strategy 2030, the Danish Medicines Agency (DKMA), long held as the embodiment of European regulatory excellence, is fine-tuning its priorities. New director Nils Falk Bjerregaard sees the DKMA’s role as a “facilitator of innovation,” supporting early-stage development and leveraging real-world data at home,…

Denmark Maja Kramp, General Manager at Ferring Nordics, discusses the company’s long-standing commitment to innovation in reproductive medicine and the pivotal role of the Nordic region in Ferring’s global strategy. She highlights the region’s strong life sciences ecosystem, Denmark’s leadership in global R&D, and the company’s values of collaboration, care, and…

Global Globally some 1.8 million children and young people (CYP) live with type 1 diabetes (T1D) and in low-and middle-income countries (LMICs) prevalence of the disease is on the rise. In many of these countries, health systems lack the resources to manage this complex chronic disease and the insulin used to…

Switzerland Daniela Marino, CEO and co-founder of CUTISS, leads a pioneering Swiss “tech-bio” company developing personalised skin grafts through advanced tissue engineering. With roots in academic research and over EUR 90 million raised, CUTISS has brought its lead product into Phase III trials, targeting burns and reconstructive surgery. Their unique approach…

Europe Dr Carolyn H. Rogers, Rushikesh S. Dasoondi and Dr Michael A. Roberts from UK and European intellectual property law firm Reddie & Grose LLP examine the intersection of personalised medicine and rare diseases and its implications for IP law.   Personalised medicine, also referred to as precision medicine, is an…

Europe Will a new ‘Critical Medicines Act’ go far enough to ensure Europe’s resilience to future health crises?   A Continent at Risk The COVID-19 pandemic exposed serious vulnerabilities in the European medicine supply chain. EU countries suddenly found themselves competing for limited supplies of sedatives and antibiotics for ICU care,…